» Authors » David van Klaveren

David van Klaveren

Explore the profile of David van Klaveren including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 130
Citations 2721
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Dekker E, van Klaveren D, Verkolf E, de Wilde R, Besselink M, OReilly E, et al.
Br J Surg . 2025 Feb; 112(2). PMID: 39967445
Background: Which patients with locally advanced pancreatic cancer may benefit from surgical exploration after induction treatment remains debated. The aim of this retrospective cohort study was to identify independent factors...
2.
van Linschoten R, van Leeuwen N, van Klaveren D, Pierik M, Pierik P, Creemers R, et al.
J Crohns Colitis . 2025 Feb; 19(2). PMID: 39945210
Background And Aims: Large registries are promising tools to study the epidemiology of inflammatory bowel disease (IBD). We aimed to develop and validate machine learning models to identify IBD cases...
3.
van Leeuwen F, Steyerberg E, van Klaveren D, Wessler B, Kent D, van Zwet E
Stat Med . 2025 Feb; 44(5):e70011. PMID: 39921554
Background: External validations are essential to assess the performance of a clinical prediction model (CPM) before deployment. Apart from model misspecification, also differences in patient population, the standard of care,...
4.
Verheul E, van Klaveren D, Lingsma H, Vos E, Hoornweg M, Siesling S, et al.
BJS Open . 2025 Feb; 9(1). PMID: 39903734
Background: Comparison of quality indicators can improve quality of care. However, case-mix adjustment is deemed essential. The aim of this study was to develop and validate case-mix adjustment models and...
5.
Smit J, Van Der Zee P, Stoof S, van Genderen M, Snijders D, Boersma W, et al.
Lancet Respir Med . 2025 Feb; 13(3):221-233. PMID: 39892408
Background: Despite several randomised controlled trials (RCTs) on the use of adjuvant treatment with corticosteroids in patients with community-acquired pneumonia (CAP), the effect of this intervention on mortality remains controversial....
6.
Kaplan Z, van Leeuwen N, van Klaveren D, Visser O, Posthuma E, van Lammeren-Venema D, et al.
BMJ Oncol . 2025 Jan; 3(1):e000264. PMID: 39886140
Objective: Acute myeloid leukaemia (AML) prognosis is enhanced with intensive remission induction chemotherapy (ICT) in eligible patients. However, ICT eligibility perceptions may differ among healthcare professionals. This nationwide, population-based study...
7.
Mikolic A, van Klaveren D, Jost M, Maas A, Shi S, Silverberg N, et al.
BMJ Ment Health . 2025 Jan; 28(1. PMID: 39819833
Background: Traumatic brain injury (TBI) is associated with an increased risk of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). We aimed to identify predictors and develop models for...
8.
Maas C, Kent D, Dinmohamed A, van Klaveren D
medRxiv . 2025 Jan; PMID: 39763519
Background: Risk-based analyses are increasingly popular for understanding heterogeneous treatment effects (HTE) in clinical trials. For time-to-event analyses, the assumption that high-risk patients benefit most on the clinically important absolute...
9.
Jongen C, Heijmen B, Schillemans W, Zolnay A, Witte M, Pos F, et al.
Clin Transl Radiat Oncol . 2025 Jan; 50:100886. PMID: 39763489
Purpose: To develop a single NTCP model for grade ≥ 2 late rectal bleeding (G2 LRB) after conventional or hypofractionated radiotherapy for prostate cancer. Methods And Materials: The development dataset...
10.
Gragnano F, van Klaveren D, Heg D, Raber L, Krucoff M, Raposeiras-Roubin S, et al.
Circulation . 2024 Oct; 151(6):343-355. PMID: 39462482
Background: Accurate bleeding risk stratification after percutaneous coronary intervention is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of patients...